• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

作者信息

Chong Elise A, Levine Bruce L, Grupp Stephan A, Davis Megan M, Siegel Don L, Maude Shannon L, Gladney Whitney L, Frey Noelle V, Porter David L, Hwang Wei-Ting, Chong Emeline R, June Carl H, Schuster Stephen J

机构信息

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.

Children's Hospital of Philadelphia, Philadelphia, PA.

出版信息

Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258.

DOI:10.1182/blood.2019002258
PMID:31554634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6872962/
Abstract
摘要

相似文献

1
CAR T cell viability release testing and clinical outcomes: is there a lower limit?嵌合抗原受体（CAR）T细胞活力释放测试与临床结果：是否存在下限？
Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258.
2
[Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].嵌合抗原受体T细胞（CAR-T细胞）治疗患者的中期随访：法语国家骨髓移植与细胞治疗协会（SFGM-TC）的建议
Bull Cancer. 2021 Dec;108(12S):S65-S71. doi: 10.1016/j.bulcan.2020.11.015. Epub 2021 Mar 4.
3
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.利用 CAR-T 细胞疗法治疗实体瘤的新方法。
Int J Mol Sci. 2021 Nov 9;22(22):12126. doi: 10.3390/ijms222212126.
4
CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma.嵌合抗原受体 T 细胞疗法治疗复发/难治性侵袭性大 B 细胞淋巴瘤。
Clin J Oncol Nurs. 2022 Nov 18;26(6):597-601. doi: 10.1188/22.CJON.597-601.
5
Medical crowdfunding to access CAR T-cell therapy.通过医疗众筹获取嵌合抗原受体T细胞疗法。
Lancet Oncol. 2019 Aug;20(8):1062-1064. doi: 10.1016/S1470-2045(19)30466-8. Epub 2019 Jul 29.
6
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].[CAR T细胞治疗患者的资格：SFGM-TC基于专家意见的协作工作]
Bull Cancer. 2021 Jul-Aug;108(7-8):725-729. doi: 10.1016/j.bulcan.2020.10.017. Epub 2021 Jan 7.
7
Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.质谱流式细胞术：用于嵌合抗原受体T细胞疗法全面免疫监测的强大平台。
Br J Haematol. 2021 Aug;194(4):788-792. doi: 10.1111/bjh.17551. Epub 2021 May 26.
8
The Promise and Challenges of CAR-T Gene Therapy.嵌合抗原受体T细胞（CAR-T）基因疗法的前景与挑战
JAMA. 2017 Dec 12;318(22):2167-2169. doi: 10.1001/jama.2017.15605.
9
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
10
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.儿童和青年复发性/难治性急性淋巴细胞白血病中 CD19 特异性嵌合抗原受体 T 细胞治疗的系统评价和荟萃分析：安全性和疗效结局。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17.

引用本文的文献

1
Stem cell therapies for diabetes.糖尿病的干细胞疗法。
Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03767-8.
2
Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer.为具有新型CAR间隔区的FiCAR T细胞产品的早期开发建立符合GMP的制造工艺和适用于相应阶段的分析方法。
Sci Rep. 2025 Mar 8;15(1):8093. doi: 10.1038/s41598-025-92736-9.
3
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.大型B细胞淋巴瘤中CAR T细胞制造失败的风险因素及患者预后：来自英国国家CAR T专家组的报告
Blood Cancer J. 2025 Mar 4;15(1):30. doi: 10.1038/s41408-025-01225-9.
4
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.用于癌症治疗的异基因嵌合抗原受体细胞疗法：取得的进展与尚存的障碍
Nat Rev Clin Oncol. 2025 Jan;22(1):10-27. doi: 10.1038/s41571-024-00959-y. Epub 2024 Nov 15.
5
Challenges of Cell Counting in Cell Therapy Products.细胞治疗产品细胞计数的挑战。
Cell Transplant. 2024 Jan-Dec;33:9636897241293628. doi: 10.1177/09636897241293628.
6
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics.从 T 细胞制造药物：工程化 T 细胞疗法的定量药理学。
NPJ Syst Biol Appl. 2024 Mar 18;10(1):31. doi: 10.1038/s41540-024-00355-3.
7
CAR-T cell manufacturing: Major process parameters and next-generation strategies.CAR-T 细胞生产：主要工艺参数和下一代策略。
J Exp Med. 2024 Feb 5;221(2). doi: 10.1084/jem.20230903. Epub 2024 Jan 16.
8
Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies.为下一代干细胞衍生免疫疗法设计T细胞发育
GEN Biotechnol. 2023 Apr 1;2(2):106-119. doi: 10.1089/genbio.2023.0008. Epub 2023 Apr 18.
9
Expanding access to CAR T cell therapies through local manufacturing.通过本地生产扩大CAR-T细胞疗法的可及性。
Nat Biotechnol. 2023 Dec;41(12):1698-1708. doi: 10.1038/s41587-023-01981-8. Epub 2023 Oct 26.
10
Post-thaw application of ROCK-inhibitors increases cryopreserved T-cell yield.解冻后应用ROCK抑制剂可提高冷冻保存的T细胞产量。
RSC Med Chem. 2023 Sep 5;14(10):2058-2067. doi: 10.1039/d3md00378g. eCollection 2023 Oct 18.

本文引用的文献

1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
2
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
3
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
4
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.